Blood Stream Infection
11
2
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
9%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia
Examination of the Large Intestine With Camera Capsule in Patients With Blood Stream Infection With Gut-associated Bacteria
Effect of the BioFire FilmArray (BCID2) for the Rapid Detection of Bloodstream Infection in Haematologic Patients With Febrile Neutropenia
Optimizing Clinical Use of Polymyxin B
Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)
Application of Nanopore Sequencing in Newly Diagnosed Acute Myeloid Leukemia Patients With Bloodstream Infection
Three-Chamber Bags Retrospective Study in Spain
Impact of Rapid Pathogen Identification From Blood Cultures (RABbIT)
Central and Peripheral Venous Catheters Associated Blood Stream Infection in ICU in Assiut University
Topical Emollient Therapy